A detailed history of Israel Englander (Millennium Management LLC) transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Millennium Management LLC holds 157,100 shares of VRTX stock, worth $77.6 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
157,100
Previous 324,816 51.63%
Holding current value
$77.6 Million
Previous $136 Million 45.77%
% of portfolio
0.04%
Previous 0.06%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$392.81 - $485.53 $71.5 Million - $88.4 Million
-182,057 Reduced 56.05%
142,759 $66.9 Million
Q1 2024

May 15, 2024

SELL
$407.69 - $446.08 $130 Million - $142 Million
-317,934 Reduced 49.46%
324,816 $136 Million
Q4 2023

Feb 14, 2024

SELL
$343.0 - $410.68 $145 Million - $174 Million
-423,968 Reduced 39.75%
642,750 $262 Million
Q2 2023

Aug 14, 2023

BUY
$314.42 - $351.91 $333 Million - $373 Million
1,059,682 Added 15060.86%
1,066,718 $375 Million
Q1 2023

May 15, 2023

SELL
$283.23 - $323.1 $93.3 Million - $106 Million
-329,526 Reduced 97.91%
7,036 $2.22 Million
Q4 2022

Feb 14, 2023

BUY
$285.76 - $321.48 $95.2 Million - $107 Million
333,024 Added 9412.78%
336,562 $97.2 Million
Q3 2022

Nov 14, 2022

SELL
$273.83 - $305.53 $78.9 Million - $88 Million
-287,965 Reduced 98.79%
3,538 $1.02 Million
Q2 2022

Aug 15, 2022

SELL
$234.96 - $292.55 $5.08 Million - $6.33 Million
-21,633 Reduced 6.91%
291,503 $82.1 Million
Q1 2022

May 16, 2022

SELL
$221.42 - $260.97 $29.6 Million - $34.9 Million
-133,717 Reduced 29.92%
313,136 $81.7 Million
Q4 2021

Feb 14, 2022

SELL
$177.01 - $223.45 $44 Million - $55.6 Million
-248,855 Reduced 35.77%
446,853 $98.1 Million
Q3 2021

Nov 15, 2021

BUY
$181.39 - $202.99 $60.1 Million - $67.2 Million
331,296 Added 90.91%
695,708 $126 Million
Q2 2021

Aug 16, 2021

SELL
$187.49 - $221.1 $102 Million - $120 Million
-541,509 Reduced 59.77%
364,412 $73.5 Million
Q1 2021

May 17, 2021

BUY
$207.02 - $241.31 $123 Million - $143 Million
592,174 Added 188.74%
905,921 $195 Million
Q4 2020

Feb 16, 2021

BUY
$207.01 - $276.09 $55.8 Million - $74.4 Million
269,398 Added 607.45%
313,747 $74.2 Million
Q3 2020

Nov 16, 2020

SELL
$255.65 - $303.1 $27.3 Million - $32.3 Million
-106,592 Reduced 70.62%
44,349 $12.1 Million
Q2 2020

Aug 14, 2020

BUY
$225.48 - $295.8 $13 Million - $17.1 Million
57,693 Added 61.87%
150,941 $43.8 Million
Q1 2020

May 14, 2020

SELL
$199.77 - $247.81 $60.8 Million - $75.5 Million
-304,556 Reduced 76.56%
93,248 $22.2 Million
Q4 2019

Feb 14, 2020

SELL
$166.71 - $223.91 $614,326 - $825,108
-3,685 Reduced 0.92%
397,804 $87.1 Million
Q3 2019

Nov 14, 2019

SELL
$166.23 - $187.09 $16.5 Million - $18.5 Million
-99,114 Reduced 19.8%
401,489 $68 Million
Q2 2019

Aug 15, 2019

SELL
$164.61 - $190.37 $133 Million - $153 Million
-805,130 Reduced 61.66%
500,603 $91.8 Million
Q2 2019

Aug 14, 2019

BUY
$164.61 - $190.37 $114 Million - $132 Million
695,522 Added 113.98%
1,305,733 $26.1 Million
Q1 2019

May 14, 2019

SELL
$163.73 - $194.7 $102 Million - $121 Million
-620,640 Reduced 50.42%
610,211 $112 Million
Q4 2018

Feb 14, 2019

BUY
$151.91 - $192.21 $33.8 Million - $42.8 Million
222,524 Added 22.07%
1,230,851 $204 Million
Q3 2018

Nov 14, 2018

BUY
$167.73 - $192.74 $57.8 Million - $66.4 Million
344,730 Added 51.95%
1,008,327 $194 Million
Q2 2018

Aug 14, 2018

BUY
$145.72 - $169.96 $13.9 Million - $16.2 Million
95,048 Added 16.72%
663,597 $113 Million
Q1 2018

May 15, 2018

SELL
$151.6 - $177.13 $100 Million - $117 Million
-659,534 Reduced 53.7%
568,549 $92.7 Million
Q4 2017

Feb 14, 2018

SELL
$137.28 - $155.55 $60.4 Million - $68.5 Million
-440,125 Reduced 26.38%
1,228,083 $184 Million
Q3 2017

Nov 14, 2017

BUY
$148.13 - $162.24 $247 Million - $271 Million
1,668,208
1,668,208 $254 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $127B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.